Skip to main content
Abrdn PLC logo

Abrdn PLC — Investor Relations & Filings

Ticker · ABDN ISIN · GB00BF8Q6K64 LEI · 0TMBS544NMO7GLCE7H90 IL Financial and insurance activities
Open in API
Filings indexed 4,552 across all filing types
Latest filing 2023-08-07 Regulatory Filings
Country GB United Kingdom
Listing IL ABDN

About Abrdn PLC

https://www.abrdn.com/en-gb

Abrdn PLC is a global investment company and asset manager formed from the 2017 merger of Standard Life and Aberdeen Asset Management. The firm offers a range of investment solutions, funds, and investment trusts. It serves a diverse client base that includes individual customers, financial advisers, wealth managers, and institutional investors. The company focuses on providing expertise and tools to help clients manage and grow their wealth, enabling them to prepare for their financial future.

Recent filings

Filing Released Lang Actions
Form 8.3 - LondonMetric Property plc
Regulatory Filings Classification · 98% confidence The document is explicitly titled 'FORM 8.3' and references 'Rule 8.3 of the Takeover Code'. This form is used for 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE' in the context of a takeover offer (LondonMetric Property plc). This type of disclosure relates to insider/significant shareholder dealings during a takeover scenario. While it involves dealings, the specific regulatory form (Form 8.3) points towards disclosures related to corporate actions/takeovers, which are often categorized under general regulatory announcements or specific insider dealing reports. Since there is no specific code for 'Takeover Code Disclosure Form 8.3', and it details personal share transactions by an entity (abrdn plc) involved in a potential takeover, it most closely aligns with 'Director's Dealing' (DIRS) or the general 'Regulatory Filings' (RNS). Given the context is a mandatory disclosure under the Takeover Code regarding interests and dealings in securities during an offer, it is a specific type of insider/significant shareholder transaction report. However, 'Director's Dealing' (DIRS) is defined as 'Report of personal share transactions by company directors and executives (insider trades)'. While abrdn plc is not strictly a director, this filing reports their position and dealings in the context of an offer, which is a form of insider/significant interest disclosure. If we must choose from the provided list, 'DIRS' covers insider transactions. If it were a general, non-takeover related insider trade, DIRS would be perfect. Since this is a mandatory disclosure under the Takeover Code, it is fundamentally a regulatory filing about security interests. Given the options, 'DIRS' is the closest fit for reporting security interests/dealings by a major party, but 'RNS' is the fallback for regulatory filings. Since the content is highly specific to insider/major shareholder activity during a takeover, and DIRS covers insider trades, I will lean towards DIRS as the most specific functional match, although RNS is also plausible as a catch-all for specific regulatory forms.
2023-08-07 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is an RNS announcement from abrdn PLC dated 07 August 2023. The title is "Transactions in own shares". The content details the purchase of ordinary shares on the London Stock Exchange on 4 August 2023, including volume, highest/lowest/VWAP prices, and a table listing individual transactions. This activity directly corresponds to the definition of a company buying back or selling its own shares, which maps to the 'Transaction in Own Shares' category (POS).
2023-08-07 English
Form 8.3 - Dechra Pharmaceuticals PLC
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE' and references 'Rule 8.3 of the Takeover Code'. This form is used to disclose interests and dealings in securities related to a takeover offer (in this case, involving Dechra Pharmaceuticals PLC). This type of disclosure, which relates to insider/significant shareholder activity during a takeover scenario, is a specific type of regulatory filing. While it involves director/insider dealings (DIRS), the context is strictly tied to a takeover bid and uses a specific Takeover Code form (Form 8.3), which is generally classified under general regulatory announcements or specific insider trading rules. Given the options, 'Director's Dealing' (DIRS) is the closest fit for reporting personal share transactions by executives/insiders, although this specific form is mandated by the Takeover Code. However, since the document is a mandatory disclosure related to a takeover bid and involves reporting interests/dealings, and there isn't a specific 'Takeover Disclosure' code, we must evaluate the closest fit. Form 8.3 is a mandatory disclosure of interests/dealings. Since it details dealings by a person controlling over 1% of securities during an offer, it strongly aligns with the spirit of insider/director dealing disclosures, even if the context is a takeover. If we consider the general nature of reporting personal transactions by significant holders/insiders, DIRS is plausible. Alternatively, since it is a mandatory filing disseminated via RNS, RNS could be a fallback. Given the specific nature of reporting dealings by a director/controller (abrdn plc) in relation to an offer, DIRS is the most specific category related to the *content* (dealing disclosure). However, Form 8.3 is a specific regulatory filing related to the Takeover Code, which often falls under general regulatory announcements (RNS) if a more specific code isn't available. Let's re-examine the definitions. DIRS is 'Report of personal share transactions by company directors and executives (insider trades)'. This document reports dealings by abrdn plc, a major shareholder/controller, during a takeover. This is a form of insider/significant holder disclosure. Given the structure and mandatory nature, RNS (General regulatory announcements) is often used for specific, non-standard regulatory forms like this. Since the document is a formal regulatory filing disseminated via RNS, and it doesn't perfectly match the general 'Director's Dealing' (which usually implies Form 3/4/5 equivalents in the US context, or specific local director disclosure rules), RNS is the safest and most accurate fallback for a specific, non-standard regulatory disclosure form like Form 8.3.
2023-08-04 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is an RNS announcement from abrdn PLC dated 04 August 2023. The title is explicitly 'Transactions in own shares'. The content details the purchase of ordinary shares on the London Stock Exchange on 3 August 2023, including volume, highest/lowest/VWAP prices, and a table of individual transactions. This directly corresponds to the definition of a report detailing the company buying back or selling its own shares, which is classified as 'Transaction in Own Shares' (POS).
2023-08-04 English
Form 8.3 - Blancco Technology Group plc
Regulatory Filings Classification · 98% confidence The document is explicitly titled 'FORM 8.3' and references 'Rule 8.3 of the Takeover Code'. This form is a 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE' related to an offer involving 'Blancco Technology Group plc'. This type of mandatory disclosure regarding interests in securities during a takeover situation is a specific regulatory filing. Since it is a mandatory disclosure related to corporate actions (takeover), and it is not a general earnings release (ER), annual report (10-K), or a general management/board change (MANG), it fits best under the general 'Regulatory Filings' category (RNS) as a specific type of regulatory submission, although it is highly specific. Given the options, RNS serves as the best fit for mandatory, non-financial core reports like this specific takeover disclosure form.
2023-08-03 English
Form 8.3 - Dechra Pharmaceuticals PLC
Director's Dealing Classification · 95% confidence The document is explicitly titled 'FORM 8.3' and references 'Rule 8.3 of the Takeover Code'. This form is used for 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE' in the context of a takeover offer (specifically mentioning 'Dechra Pharmaceuticals PLC' as the offeree). This type of filing relates to insider dealing disclosures during a takeover scenario. While it is a regulatory filing, the specific nature of reporting director/insider dealings related to a takeover makes it distinct from general Director's Dealing (DIRS) which usually refers to Form 3, 4, or 5 filings under SEC rules, or general regulatory announcements (RNS). However, among the provided codes, 'Director's Dealing' (DIRS) is the closest category for reporting personal share transactions by executives/insiders, even though this specific form (Form 8.3) is mandated by the UK Takeover Code. Given the options, DIRS captures the essence of reporting insider transactions, although RNS is a possible fallback if DIRS is strictly interpreted as only SEC insider forms. Since this is a disclosure of interests/dealings by a major shareholder/controller during a takeover, DIRS is the most appropriate specific classification for insider transaction reporting.
2023-08-03 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.